Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders
J Neurol 270(2):851863 Wharton S et al (2022) Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
Body composition scans provide a detailed overview of key metrics related to body fat, lean mass distribution, and metabolic indicators
Payers hesitation to cover GLP-1s for weight loss is also fueled by employer plan sponsor concerns about up-front costs of the drugs
Pharmaceutical GLP-1 agonistssuch as semaglutidehave become popular, but they are synthetic, require prescriptions, and may carry side effects with long-term use
Some ingredients in GLP-1 patches may act as stimulants and could raise blood pressure or interact with other medications